The Sompo, Relx and Fujitsu-backed big data analytics provider, valued at more than $20bn in 2015, has revealed it has confidentially filed for a public listing.

Novo and Sanofi are among the investors that could exit Yale's mineralisation disease therapy developer, which has filed to raise up to $86.3m.

Amgen-backed immuno-oncology spinout Immatics has gone public through a reverse merger with special purpose acquisition company Arya Sciences.

Novo, GSK and Amgen-backed NK oncology therapy developer Nkarta Therapeutics has set a range that will net it between $140m and $160m.

Celgene is set for an exit having invested $17m in small molecule cancer drug developer Nurix Therapeutics five years ago.

Novo and Sanofi are among the investors that could exit the mineralisation disease therapy developer, which has filed to raise up to $86.3m.

University of Tübingen’s immuno-oncology spinout Immatics has undertaken a reverse merger with special purpose acquisition company Arya Sciences to list in the US.

The bankrupt satellite internet system developer, which had raised more than $3bn from multiple corporates, has been acquired by a consortium including existing investor Bharti.

The student aid service has been bought by CampusLogic after raising more than $31m from investors including Salesforce Ventures.